Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
TetherMax Rebranding Highlights Official Exchange Partnerships and Transparent Operations 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Meta Says States Seek $1.4 Trillion in Penalties Over Teen Social Media Addiction Lawsuit 
Barclays Downgrades Siemens Energy as Valuation Seen Near Peak 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Shell Raises Q2 Upstream Outlook, Flags Qatar Gas Hit as Shares Rise 
SAN DIEGO, May 08, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, publishes scientific posters with dynamic audio narration. More than a dozen posters were presented at the recent American Association of Cancer Research’s (AACR) 2018 meeting and are now available to watch and download, https://www.crownbio.com/posters/
These scientific posters describe innovations in CrownBio’s Internal R&D focusing on preclinical oncology research. The most compelling work is now available on-demand and narrated by CrownBio scientists. The library of poster presentations includes details on the development and application of several innovative humanized models, a new largescale ex vivo PDX drug screening service and a novel IDO1 inhibition assay platform. Collectively, the data demonstrate CrownBio’s unique capacity to enhance knowledge, guide development decisions and advance immunotherapy programs.
“CrownBio is providing unfettered access to CrownBio’s innovative research with scientific colleagues worldwide,” said Dr. Henry Li, CrownBio’s Vice President of Translational Oncology. “We are committed to sharing with scientists globally the cutting-edge tools that are available to accelerate, inform and enlighten contemporary evaluation of cancer therapies and immunotherapies.”
“Crown Bioscience is committed to making valuable contributions to the scientific community,” said Dr. Jean Pierre Wery, Crown Bioscience’s Chief Executive Officer. “By providing these posters, narrated by the experts behind the science, we hope to deliver insights researchers can use to advance their preclinical drug development programs.”
The library of narrated posters can be found on Crown Bioscience’s website, https://www.crownbio.com/posters/
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. [email protected]
